Mesenchymal stromal cells for the treatment of osteoarthritis of knee joint: context and perspective

Gupta, Pawan Kumar; Thej, Charan

doi:10.21037/atm.2019.07.54

Cited by 3 publications

(1 citation statement)

References 23 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disease onset is independent of self-reactivity, but the immune response is involved in its progression [50]. As MSCs contribute to rehabilitating damaged joints [51], scientists have investigated these cells' immunological and regenerative role in osteoarthritis. Recent data indicated that accumulating p16INK4a-positive senescent MSCs is a marker of OA in murine synovial tissue [52].…”

Section: Osteoarthritismentioning

confidence: 99%

Immunosenescence of Mesenchymal Stem Cells and Autoimmune Diseases; the Dark Side of Immune System

2021

View full text Add to dashboard Cite

Our understating of the mechanisms underlying the immunomodulatory properties of mesenchymal stem cells (MSCs) has greatly advanced during previous decades.Considering their unique regulatory effects, numerous applications have been establishedfor treating autoimmune diseases. However, cellular senescence and inefficient functions were found in MSCs isolated from autoimmune patients when they were particularly utilized in autologous settings. Several attempts have beenconducted to provide an in-depth understanding of mechanisms involved in MSC senescence andits negative impacts on autoimmune disease onset/ progression.Accordingly, indirect evidence of the role of immunosenescent MSCs hasbeen reported during the immunopathogenesis of systemic sclerosis, osteoarthritis, systemic lupus erythematosus, diabetes, psoriasis, and immune thrombocytopenia. This connection is mediated primarilythroughthe reduced self-renewability of MSCs and their abnormal immunoregulatory functions in the polarization of immune cells.Such knowledge is critical for developing therapeutic interventions to re-induce autoimmune patients' immune balance.To further explore the basic and clinical characteristics of MSC senescence in autoimmune disorders, this review comprehends the available information regarding molecular mechanisms and cellular interactions that finally perturb immuno-homeostasis of MSCs.

show abstract

Section: Osteoarthritismentioning

confidence: 99%

Immunosenescence of Mesenchymal Stem Cells and Autoimmune Diseases; the Dark Side of Immune System

2021

View full text Add to dashboard Cite

show abstract

Latest advances to enhance the therapeutic potential of mesenchymal stromal cells for the treatment of immune-mediated diseases

Ceruso

Gonzalez‐Pujana

Igartua

et al. 2021

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

The Efficacy of Bone Marrow Stem Cell Therapy in Hip Osteoarthritis: A Scoping Review

Perez,

Warburton,

Philippon

et al. 2024

HSS Journal®: The Musculoskeletal Journal of Hospital for Speci

View full text Add to dashboard Cite

Background: Hip osteoarthritis (HOA) is a prevalent degenerative joint disease with various treatment approaches. Biological agents, such as bone-marrow derived stem cells (BM-MSC) therapy, have recently been proposed as a treatment option in the management of HOA. Purpose: We sought to further analyze the use of BM-MSC therapy by investigating the following questions. What is the standard preparation and practice? Does a dose response exist between stem cell therapy and clinical outcome? Does BM-MSC therapy alone produce effective clinical outcomes? Methods: We conducted a scoping review using the Methodological Expectations of Cochrane Intervention Reviews Manual and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines for scoping reviews. A comprehensive search of PubMed, Embase, Cochrane CENTRAL, Scopus, SPORTDiscus, Cumulative Index to Nursing and Allied Health Literature, and Web of Science Core Collection was performed in June 2023 of studies using exclusively BM-MSC injections for the treatment of HOA. Study characteristic, injection preparation and dosage, clinical outcome measures, and adverse effect data were extracted and interpreted by 3 reviewers. Results: Seven studies with a total of 72 patients met the inclusion criteria. Clinical outcome following intra-articular injection of BM-MSCs was measured using the numerical pain scale, the Western Ontario and McMaster Universities Osteoarthritis Index, the visual analogue scale, and other scores, all of which showed reduction in pain and increase in functional ability across studies. Conclusions: This scoping review found that the efficacy of BM-MSC therapy alone in the treatment of HOA appeared beneficial, improving clinical outcomes in each study. All 7 studies used “low-dose” injections with variable follow-up times; thus, a clear dose–response relationship cannot be drawn. Future studies using high doses and analyzing long-term effects of BM-MSC injections in HOA are needed.

show abstract

Mesenchymal stromal cells for the treatment of osteoarthritis of knee joint: context and perspective

Cited by 3 publications

References 23 publications

Immunosenescence of Mesenchymal Stem Cells and Autoimmune Diseases; the Dark Side of Immune System

Immunosenescence of Mesenchymal Stem Cells and Autoimmune Diseases; the Dark Side of Immune System

Latest advances to enhance the therapeutic potential of mesenchymal stromal cells for the treatment of immune-mediated diseases

The Efficacy of Bone Marrow Stem Cell Therapy in Hip Osteoarthritis: A Scoping Review

Contact Info

Product

Resources

About